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Cervical screening for carcinogenic human papillomavirus (HPV) infection is being considered for low-income countries.
Effectiveness requires targeted screening in older women in whom prevalent infections are more likely to be persistent and
predictive of precancer. Some studies in West Africa have found unusually high HPV prevalences across all adult ages, which
may reduce the positive predictive value (PPV) of HPV-based screening, if positivity in older women does not sufficiently
predict elevated risk. We conducted a population-based study in rural Nigeria to identify HPV prevalence and associated
cervical abnormalities. Using stratified random sampling, we enrolled women age 151. Nonvirgins had a cervical exam
including liquid-based cytology and PCR HPV DNA testing from residual cytology specimens. Two-thirds of invited women
participated, and 14.7% had detectable carcinogenic HPV, a proportion that did not decline with age (p-trend 5 0.36) and
showed slight peaks in the 15–29 and 60–69 age groups. Among women of the age typically considered for screen-and-treat
programs (30–49 years), 12.8% were HPV positive, and the PPV for high-grade or worse cytology was 16.4%. Comparatively,
women age < 30 were more likely to be HPV positive (18.9%, p 5 0.03) with a lower PPV (4.2% p 5 0.05). Among women
age 501 (typically excluded from screening in resource-poor settings because inexpensive treatment is not available), HPV
positivity was 14.2% with a PPV of 13.9%. In Irun and similar settings where HPV does not decline with age, HPV-based
screen-and-treat programs might be feasible for mid-adult women because prevalence is sufficiently low and positivity
predicts elevated risk of more easily treated precancer.
Virtually all cases of cervical cancer worldwide are caused by
persistent infection with one or more of approximately a dozen
carcinogenic genotypes of human papillomavirus (HPV).1–3
Although effective HPV vaccines have been developed, none
has immediate promise for low-income countries where the
cancer burden is disproportionately high (>85% of total global
burden),4 because of relatively high cost and lack of feasibility
of a three-dose regimen. With adequate screening and treat-
ment, the vast majority of cervical cancer can be prevented
during the typical 10–15þ year precancerous period.5,6 Yet, the
conventional model (Pap smear screening, followed by colpo-
scopically directed biopsy of women with abnormal screening
to determine who needs treatment) is neither sufﬁciently devel-
oped nor sustainable in most low-income countries.7 In con-
trast, a one-visit screen-and-treat approach is promising where
women who screen positive receive treatment with cryother-
apy.8 In particular, HPV-based screening is now being
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proposed. Yet, effective application of an HPV-based screen-
and-treat program requires a thorough understanding of the
underlying natural history of HPV in a target population.
In most populations, the age-speciﬁc prevalence pattern of
HPV infections observed in sexually active women resembles
that of a typical sexually transmissible infection. Incidence and
prevalence peak at young ages soon after the start of sexual activ-
ity, with a subsequent decline as infections clear, with fewer inci-
dent infections as patients age.9 In these regions where HPV
prevalence declines with age, the optimal age for HPV-based
screening is in the 30- to 49-year age group—before the upturn
in invasive cancer incidence. At this age in most places, carcino-
genic-type HPV infection is detected in virtually all women with
precancer or early-stage cancer but only 5–10% of the general
population.9 Therefore, HPV testing, when used properly at these
correct ages, provides excellent risk stratiﬁcation (acceptable posi-
tive predictive values (PPVs) and extremely good negative pre-
dictive values).10,11 HPV-positive women (the group containing
the women with cancer risk) can be treated immediately, using
cryotherapy of the cervix in particular,8 whereas HPV-negative
women can be reassured that their cancer risk is minimal during
the subsequent years.12 One or two screening rounds per lifetime
can reduce cancer risk substantially.13
Unfortunately, implementation of HPV-based screen-and-
treat programs in some regions is complicated by unusual
age-speciﬁc HPV prevalence patterns.14–17 In particular, high
HPV prevalence at all ages has been reported in some, but
not all, population-based HPV studies conducted in sub-
Saharan Africa, such as areas of West Africa.16–18 We do not
know the meaning of the elevated HPV prevalences at older
ages in speciﬁc regions of Africa. Most of these HPV preva-
lence studies have not considered either concurrent age-spe-
ciﬁc cytologic or histologic status of the participants; thus,
there is an unclear association with cervical neoplasia.
One such study was conducted in a highly mobile urban
setting of Nigeria, the most populous country in Africa, with
150 million inhabitants and a high burden of cervical cancer
(age-standardized incidence of 33 per 100,000 women). The
high prevalence across all adult age groups (20% of women
were carcinogenic HPV positive) would imply lower PPV
and subsequently preclude the effective use of HPV screening
if elevated HPV positivity at older ages was not associated
with elevated risk of cervical precancer (n.b.: age-related cy-
tology was not analyzed in this project).
One study cannot be generalized to a huge and diverse pop-
ulation; we were concerned that the high HPV prevalences in
older women from urban Ibadan might not be representative
of a large part of the population (or West Africa) living in rural
areas.18 To further our understanding of the epidemiology of
HPV infection and cervical neoplasia in Nigeria and clarify
how screening might be optimized to ﬁt the epidemiologic pat-
tern, we conducted a population-based, cross-sectional screen-
ing study of age-speciﬁc HPV prevalence and cytology in
another part of Yoruban Nigeria, among 1,500 women in the
rural southwestern state of Ondo.
Material and Methods
Irun is a large rural village in which subsistence farming is the
predominant occupation. The community is serviced by one
local government health clinic, used mainly for primary care,
and one general hospital. Residents have minimal education
and a typical household earns 20,000–40,000 Naira per month
(US$ 170–340). About half of the residents of Irun are Chris-
tian, whereas the other half is Muslim, though most ascribe to
traditional beliefs as well. The typical family consists of the
head of a household with one or more wives and several chil-
dren belonging to each wife, all living within the same house.
A census done by local health workers (in which house-
hold heads were surveyed) found that approximately two-
thirds of 501 houses (roughly one-half of village) were home
to more than one household and one-eighth of households
contained more than one wife. Therefore, we chose the house
as the sampling unit to avoid possible adverse community
reaction if not all women in a house were invited. We
selected all houses known to have a household with co-wives
and a simple random sample of the remaining houses to
reach 2,100 women (439 houses total). Local health workers
visited women in their homes. Those meeting eligibility crite-
ria (not pregnant and without hysterectomy, 15þ years old
and living in the house for more than 3 months) were asked
to enroll after providing informed consent; participants were
assigned a clinic appointment. Unmarried women age 15–21
were coconsented by their legal parent/guardian as well.
Upon arrival at the clinic, women completed a second
informed consent with more detailed information on clinic
procedures. For nonvirgins, nurses conducted a cervical exam
involving the collection of cervical cells using a broom-type
device and an endocervical brush. Both specimens were
placed into Preservcyt buffer (Hologic, Marlborough, MA)
for liquid-based cytology and an HPV DNA test.
Cytology slides were prepared and read in the United States.
The presence of high-risk HPV genotypes was determined
from residual cytology specimens. HPV DNA was ampliﬁed
using Gold Taq and a modiﬁed MY09-MY11 PCR-based
method that included additional primers for HPV30, 35, 39, 51
and 68 as well as primers to amplify a cellular beta-globin frag-
ment as a control for ampliﬁcation.19 PCR products were typed
by dot-blot hybridization using type-speciﬁc probes as previ-
ously described.19 We considered the 13 most carcinogenic
types for HPV positivity: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59 and 68. The numeric measure of signal strength (1–5)
was used as a validated semiqualitative measure of viral load.20
The protocol was reviewed and approved by both Niger-
ian and NCI institutional review boards (NCT 00804466).
Appropriate diagnosis and treatment among screen-positive
women is now underway, using a combination of cryother-
apy, LEEP and surgery.
We calculated the age-stratiﬁed proportion of women
infected with carcinogenic HPV and cytologic abnormalities.
Bivariate analyses measured the risk of carcinogenic HPV
infection among women with abnormal cytology as well as
E
pi
de
m
io
lo
gy
2112 Age-specific HPV prevalence in Irun, Nigeria
Int. J. Cancer: 130, 2111–2117 (2012) VC 2011 UICC
the risk of abnormal cytology given carcinogenic HPV infec-
tion. Differences by age were considered using standard con-
tingency table analysis with Chi-square statistics, unless oth-
erwise noted. To rule out the possibility that our ﬁndings
were distorted by oversampling women who lived in houses
containing a household with more than one co-wife, we
stratiﬁed our results by co-wife status in the household (no
co-wife vs. more than one co-wife); there were no notable
differences. Analyses were performed using Stata 11.0 analytic
software (Stata Corp LP, College Station, TX).
Results
Among 439 houses visited, we were able to contact 2,091
women who were eligible for enrollment (Fig. 1). Approxi-
mately one-third (n ¼ 671) of these women either refused
enrollment at home or did not attend the clinic visit. Partici-
pation varied by age: women 15–20 were less likely to enroll
and attend the clinic visit (43.1 vs. 74.3% among women over
20, p < 0.01).
Of 1,282 nonvirgins attending the screening visit for
whom HPV DNA test results were available, 14.7% were
infected with one or more carcinogenic HPV genotypes. Fig-
ure 2 separately presents the independent results of HPV
testing (line) and cytology (bar) by age. The proportion of
HPV positive did not decline with age (Chi-square p-trend ¼
0.36) and had slight peaks in women 15–29 (18.9%) and 60–
69 (17.6%) years old, compared to 12–14% in mid-adult
women. Cytologic abnormalities were most common in the
youngest women (ages 15–29) compared to women age 30 or
older (15.0 vs. 8.0%, p < 0.01); no second peak of abnormal
cytology results was observed in older women. When cytol-
ogy was abnormal, severity varied by age: younger women
were more likely than older women to have a low-grade ab-
normality (86.5% of abnormal results in women under 30 vs.
Figure 1. Consort diagram.
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64.0% in women 30 or older, p ¼ 0.01), and older age was
associated with higher risk of high-grade intraepithelial lesion
(HSIL) or worse abnormality (36.0% of abnormal results in
women 30 or older vs. 13.5% in women under 30, p ¼ 0.01).
Overall, 10.0 and 4.1% of women were infected with one
or more HPV genotypes in either the alpha-9 or alpha-7 spe-
cies, respectively, with alpha-9 types HPV16, 31, 35, 52 and
58 being most common (2.0% or more) (Table 1). A total of
19.2% of women infected with a carcinogenic HPV genotype
were concurrently infected with at least one other carcino-
genic genotype. HSIL or worse cytology was most often asso-
ciated with HPV16 and/or 35 (21.9 and 18.8%, respectively).
Among women with atypical squamous cells of undeter-
mined signiﬁcance (ASC-US) or low-grade squamous intrae-
pithelial lesion (LSIL) vs. HSIL or worse cytology, the per-
centage concurrently testing positive for one or more of the
13 carcinogenic HPV genotypes was 51.3 and 65.6%, respec-
tively (Table 1). This result was observed across all age
groups (data not presented).
Among HPV-positive women, those with ASC-US/LSIL,
HSIL or worse were more likely than those with normal cy-
tology to have an HPV infection with a PCR signal strengths
of 4 or 5 (80.5 and 76.2% vs. 50.9%, respectively, p < 0.05).
Notably, however, in terms of absolute numbers, 53.8% of
106 women with an elevated HPV PCR signal strength had
normal cytology (Table 1). Signal strength, a semiquantitative
measure of viral load, was not associated with age (data not
presented, one-way ANOVA F[1, 1280] ¼ 0.95; p ¼ 0.33).
In a complementary analysis, we considered the PPV of
HPV testing, that is, how many HPV-infected women had
cytologic abnormalities (versus the analysis above which con-
sidered how many women with cytologic abnormalities had
HPV). Restricting our analysis to 188 HPV-positive women
with cytology results (Table 2), most (64.6%) did not have a
concurrent cytologic abnormality, especially over age 49. Age
trends in this analysis were similar to those in the unpaired
analysis shown in Figure 2; HPV infections in younger
women were more likely than those in older women to be
associated with ASC-US or LSIL (41.7% in women <30 vs.
16.5% in women 30 or older, p < 0.01). Conversely, HPV
infections in older compared to younger women were more
likely to be associated with HSIL or worse cytology, although
this did not reach statistical signiﬁcance (15.0% in women 30
or older vs. 4.2% in women under 30, p ¼ 0.05). Among 55
HPV-positive women in the age range considered optimal for
a screen-and-treat program (30–49 years), 16.4% had an
HSIL or worse cytologic abnormality.
Discussion
Our population-based study in a rural Nigerian town
achieved widespread participation among women over age 25
and found that, on an average, 14.7% of women were preva-
lently infected with carcinogenic HPV; rates were highest
among the youngest and oldest women. Although most HPV
infections were not linked to cytologic abnormalities, we did
observe distinct trends across age groups that are important
for planning screen-and-treat programs. HPV infections in
the youngest women (<30 years) were more often associated
with low-grade cytologic changes; these represent active,
newly acquired infections too numerous and benign to treat
immediately. For women in the age group typically consid-
ered for screen-and-treat programs (30–49 years), 12.8%
(95% conﬁdence interval: 9.8–15.9%) were infected with car-
cinogenic HPV, of whom 16.4% had concurrent high-grade
or worse cytologic abnormalities. An unknown fraction of
the remainder is at risk of developing high-grade abnormal-
ities in the future, increasing the long-term PPV of carcino-
genic HPV testing in this age group. We believe that screen-
and-treat programs would most logically target this age
group. Given the acceptable safety of cryotherapy, a PPV of
at least 16.4% for the endpoint of high-grade or worse cytol-
ogy might be judged high enough for immediate treatment in
places without other cervical cancer prevention options.
Among women age 50 or greater (an age not typically
considered for screen-and-treat programs), HPV infection
was also associated with high-grade cytologic abnormality.
This elevated risk of high-grade abnormalities likely reﬂects
the lack of previous screening and treatment in this popula-
tion and subsequent accumulation of high-grade lesions. The
lack of low-grade lesions could reﬂect atrophy at that age.
Unfortunately, no widely accepted treatment option is avail-
able for low-cost screening and treatment of older women,
because cryotherapy is commonly believed to be ineffective
Figure 2. Percent of women with given cytologic abnormalitya and
PCR positive for one or more 13 carcinogenic HPV genotypes by
age (mean and median age ¼ 45 years). aClassiﬁcation by
severity: atypical squamous cells of undetermined signiﬁcance
(ASC-US), low-grade squamous intraepithelial lesion (LSIL) and
high-grade intraepithelial lesion (HSIL) cancer. Shaded area
highlights age considered optimal for screen-and-treat program:
HPV prevalence is decreasing, risk of high-grade or worse cytology
is increasing and women are not yet at elevated risk of cancer
cytology.
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treating lesions likely inside the endocervical canal and
unreachable by the cryoprobe (n.b.: A few studies have sug-
gested that cryotherapy is perhaps 50–90% efﬁcacious in
women with lesions that extend into the endocervical
canal,21–24 but no deﬁnitive study has shown the efﬁcacy of
cryotherapy in older women.). In any case, although this old-
est age group was at greatest risk of high-grade cytology,
their disease would be caught and treated years earlier
through HPV-based screening, once a screen-and-treat pro-
gram targeting younger women had been in operation for a
sufﬁcient length of time.
Our ﬁndings are similar to those previously reported in
nearby urban Ibadan, Nigeria.16 Although the overall preva-
lence of carcinogenic HPV was statistically higher in Ibadan
than our ﬁndings (18.3 vs. 14.7%, Chi-square p ¼ 0.02), this
difference could be due to variations in PCR assays. Still a
similarly elevated prevalence was sustained across all ages.
Our observed age curve was similar to shallow U-shaped
curves reported in other cohort studies in rural Gambia and
other areas of Africa and Latin America.9,18,25,26 Our study
found an elevated occurrence of HPV35 (2.4%) and observed
that HPV35 was present in 18.8% of high-grade cytology
abnormalities, second highest to HPV16 (21.9%). Such over-
representation of HPV35 has been observed in other studies
across Africa.16,17,27–29
We did not obtain human immunodeﬁciency virus (HIV)
seroprevalence data from women in our study. However, we
believe that HIV is unlikely to explain the elevated HPV
prevalence in older women.
Our ﬁeld study confronted several limitations worth men-
tioning. Participation was lowest among women age 20,
preventing deﬁnitive interpretations of the prevalence of
HPV in young women age 15–20. The risk of HPV infection in
this age group was lower than anticipated for a sexually
Table 1. Cytology results and risk of concurrent type-speciﬁc carcinogenic HPV infection for 1,282 women
Total (col %)
Cytology (col %)1
Normal ASC-US/LSIL2 HSIL13
n % n % n % n %
HPV negative for all 13 types4 1094 85.3 962 89.5 39 48.8 11 34.4
Any of 13 carcinogenic types 188 14.7 113 10.5 41 51.3 21 65.6
HPV16 27 2.1 16 1.5 3 3.8 7 21.9
HPV18 17 1.3 13 1.2 1 1.3 2 6.3
HPV31 32 2.5 21 2.0 6 7.5 3 9.4
HPV33 5 0.4 2 0.2 0 0.0 1 3.1
HPV35 31 2.4 16 1.5 7 8.8 6 18.8
HPV39 6 0.5 3 0.3 2 2.5 0 0.0
HPV45 7 0.6 4 0.4 0 0.0 2 6.3
HPV51 20 1.6 9 0.8 9 11.3 1 3.1
HPV52 29 2.3 20 1.9 7 8.8 2 6.3
HPV56 9 0.7 6 0.6 3 3.8 0 0.0
HPV58 31 2.4 18 1.7 7 8.8 1 3.1
HPV59 6 0.5 4 0.4 2 2.5 0 0.0
HPV68 10 0.8 8 0.7 2 2.5 0 0.0
All types in alpha-7 species5 52 4.1 37 3.4 8 10.0 4 12.5
All types in alpha-9 species6 130 10.1 76 7.1 26 32.5 17 53.1
Infected with 2þ carcinogenic types7 36 2.85 24 2.2 6 7.5 3 9.4
PCR signal strength8
1 9 4.8 7 6.3 1 2.4 0 0.0
2–3 67 35.8 48 42.9 7 17.1 5 23.8
4–5 111 59.4 57 50.9 33 80.5 16 76.2
TOTAL (row %) 1,282 100.0 1,075 90.6 80 6.7 32 2.7
1Cytology results are not available for 95 women. 2Atypical squamous cells of undetermined signiﬁcance/low-grade squamous intraepithelial lesion
(ASC-US/LSIL) include eight diagnoses of ASC, rule out HSIL (ASC-H) and six diagnoses of atypical glandular cells (AGC), not otherwise speciﬁed.
3High-grade intraepithelial lesion (HSIL) includes three diagnoses of carcinoma, one diagnosis of AGC, favor neoplasia (AGC-FN) and one woman
with both AGC-FN and ASC-H cytologic diagnoses. 4HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. 5HPV genotypes 18, 39,
45, 59, 68, 70 and 85. 6HPV genotypes 16, 31, 33, 35, 52, 58 and 67. 7Among 188 women with any carcinogenic HPV infection, 19.2% were
infected with more than one genotype. 8If woman was infected with more than one carcinogenic HPV genotype, the highest signal strength is
reported. Column percents are among HPV-positive women.
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transmitted infection, and it is possible that our study failed to
identify an early crest of HPV infection following the begin-
ning of sexual activity in the teenage years. In addition, our
understanding of HPV prevalence and cytologic abnormalities
is most challenging for women over 70 years old. In our study,
HPV prevalence declined in this age group, and we hypothe-
size that this marked difference was caused by poor sampling
from atrophic or distorted cervices. Conversely, the prevalence
of ASC-US abnormalities was unexpectedly high in this age
group and again likely represents increased benign abnormal-
ities including those associated with atrophy.
Despite using standard liquid-based collection and proc-
essing of cytology samples, expert cytopathologists in the
United States found some of the specimens difﬁcult to inter-
pret because of poorly preserved and shredded cell material
as well as grossly bloody specimens. Yet, we note that the
proportion of women with any cytologic abnormality (9.4%)
in Irun was similar to the few available population-based
studies from West Africa (6.7–9.5%).16–18
In summary, we conclude that in some West African set-
tings like Irun, HPV screening might have acceptable per-
formance characteristics if testing is tailored to the underly-
ing, age-speciﬁc prevalence and PPV of HPV infection for
identifying cervical precancer. Women age 30–49 are optimal
candidates, because they are past the initial peak of transient
HPV infection and have reached the age when there is
increasing probability of detecting treatable, high-grade dis-
ease. The remaining dilemma is how to prevent cervical can-
cer in older women, for whom treatment with cryotherapy
might fail.
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